Navigation Links
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
Date:4/21/2009

Data Selected for Presentation Highlights Anti-Tumor effects of KRX-0401 (Perifosine)

NEW YORK, April 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the company's lead anti-cancer compound, at the American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado.

Abstracts selected for presentation today, Tuesday, April 21, 2009, are as follows:

Abstract 3205:

Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models.

Author(s): Zhijie Li, Fei Tan, Jenna Tong, Amy McKee, Carol Thiele. National Cancer Inst., Bethesda, MD

Time/location: 8:00 AM - 12:00 PM, Hall B-F, Poster Section 10, # 13

Abstract Summary: In vitro studies in neuroblastoma cell lines indicate that perifosine treatment induced inhibition of Akt phosphorylation, and decreases of cell survival. In vivo studies of perifosine treatment led to significant increases in neuroblastoma tumor bearing mouse survival. In summary, Investigators conclude that the data indicates that as a single agent, perifosine targets activation of Akt in neuroblastoma cells and xenografts, and significantly inhibits tumor growth.

Abstract 4794:

Targeting breast cancer stem cells through inhibition of PI3-K/Akt/B-catenin signaling

Author(s): Korkaya Hasan, Amanda K. Paulson, Max S. Wicha. University of Michigan, Ann Arbor, MI

Time/location: 3:10 - 3:25 PM, Room 205-207, Colorado Convention Ctr.

Session Title: Cancer Stem Cell Approaches for Identification and Targeting

Abstract Summary: According to In
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 BioHealth ... on commercializing market-relevant biohealth innovations and increasing access to ... announced today that venture capitalist, Tania Fernandez , ... advisor. Dr. Fernandez will be a member of the ... will provide up to $50 million in seed and ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Contract Research Organization Exceeds Expectations, MEMPHIS, ... Contract Research,Organization exclusively focused on oncology, announced ... exceeded projections as the company continues,to experience ... to,ACORN,s ability to consistently exceed client expectations, ...
... Pharma, Inc., a,diversified specialty pharmaceutical company, announced ... issues in the treatment of moderate to,severe ... dry eye medication Lacrisert(R),(hydroxypropyl cellulose ophthalmic insert), ... helps to retain,moisture, stabilize the tear film, ...
... -- 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company ... primarily in China,today announced that it has filed ... for approval of NuLeusin for the treatment of ... is expected to,be the only treatment of this ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Clinic researchers have designed a new tool for identifying ... Stephen Ekker, Ph.D., succeeded in switching individual genes off ... development. The study appears in the journal Nature ... on health-related problems such as how cancerous cells spread, ...
... The May issue of JAMIA, the top-ranked journal reporting ... scientific researchin print and onlineon healthcare,s hottest HIT-related topics, ... Editor-in chief Lucila Ocho-Machado bullets some of the rich ... "A secure protocol for protecting the identity ...
... NEW BRUNSWICK, N.J. From a bucket of seawater, scientists ... organisms as different as coral reefs and human disease. By ... demonstrated a possible way to address diverse questions such as ... it is about some Antarctic algae that allows them to ...
Cached Biology News:In a genetic research first, Mayo Clinic turns zebrafish genes off and on 2In a genetic research first, Mayo Clinic turns zebrafish genes off and on 3JAMIA reports on people, their information needs and social networks 2From a bucket of seawater, new understanding of the ocean 2From a bucket of seawater, new understanding of the ocean 3
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Human TSLP MAb (Clone 258136)...
Biology Products: